Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management

被引:94
|
作者
Pandey, Sanjay [1 ]
Srivanitchapoom, Prachaya [2 ]
机构
[1] Govind Ballabh Pant Postgrad Inst Med Educ & Res, Dept Neurol, Acad Block,Room 507, New Delhi 110002, India
[2] Mahidol Univ, Fac Med, Div Neurol, Dept Med,Siriraj Hosp, Salaya, Nakhon Pathom, Thailand
关键词
Dopamine; dyskinesia; levodopa; Parkinson's disease; NONHUMAN PRIMATE MODEL; PARKINSONS-DISEASE; L-DOPA; MOTOR FLUCTUATIONS; DOUBLE-BLIND; ANTAGONIST ISTRADEFYLLINE; EFFICACY; AMANTADINE; SYMPTOMS; COMPLICATIONS;
D O I
10.4103/aian.AIAN_239_17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients treated with levodopa. This side effect is usually encountered after long duration of treatment, but occasionally, this may be seen even after few days or months of treatment. LID is broadly classified as peak-dose dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control. Treatment of LID requires careful history taking and clinical examination to find the type of dyskinesia as different approach is required for different types. Changes in dopaminergic medication including continuous dopaminergic stimulation are very helpful in the management of peak-dose dyskinesia. Different types of surgical approaches including unilateral pallidotomy and deep brain stimulation have given very good result in patients, who cannot be managed by medications alone. The surgical management of LID is dealt with in detail in another review in this series.
引用
收藏
页码:190 / 198
页数:9
相关论文
共 50 条
  • [41] Risk factors for the development of levodopa-induced dyskinesia
    Schaeffer, E.
    Huber, H.
    Liepelt-Scarfone, I.
    Berg, D.
    MOVEMENT DISORDERS, 2012, 27 : S137 - S138
  • [42] LEVODOPA-INDUCED DYSKINESIA - REVIEW, OBSERVATIONS, AND SPECULATIONS
    NUTT, JG
    NEUROLOGY, 1990, 40 (02) : 340 - 345
  • [43] Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
    Zheng, Chang-Qing
    Fan, Hong-Xia
    Li, Xiao-Xian
    Li, Jing-Jie
    Sheng, Shuo
    Zhang, Feng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Dysregulation of BET proteins in levodopa-induced dyskinesia
    Figge, David A.
    Standaert, David G.
    NEUROBIOLOGY OF DISEASE, 2017, 102 : 125 - 132
  • [45] Measurement of Levodopa-Induced Dyskinesia with Inertial Sensors
    Chung, Kathryn A.
    El-Gohary, Mahmoud
    Lobb, Brenna M.
    McNames, James
    NEUROLOGY, 2009, 72 (11) : A65 - A65
  • [46] Levodopa-induced dyskinesia and striatal signaling pathways
    Pisani, Antonio
    Shen, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) : 2973 - 2974
  • [47] Molecular mechanisms underlying levodopa-induced dyskinesia
    Calabresi, Paolo
    Di Filippo, Massimiliano
    Ghiglieri, Veronica
    Picconi, Barbara
    MOVEMENT DISORDERS, 2008, 23 : S570 - S579
  • [48] Levodopa-induced dyskinesia in Parkinson’s disease
    J. M. Brotchie
    J. Lee
    K. Venderova
    Journal of Neural Transmission, 2005, 112 : 359 - 391
  • [49] Levodopa-Induced Dyskinesia: "TRAP"ping the Culprit
    Prasad, Shweta
    Pal, Pramod Kumar
    MOVEMENT DISORDERS, 2018, 33 (05) : 761 - 761